RecruitingMetastatic Solid Tumors
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Eligible age
18–99 yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.
Sponsor: Erasca, Inc.
You may qualify if…
- ✓ Age ≥ 18 years
- ✓ Willing and able to give written informed consent
- ✓ Pathological documentation of tumor type and mutation prior to the first dose of study drug(s), for applicable cohorts.
- ✓ There is no available standard systemic therapy available for the patient's tumor histology and/or molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy. Does not apply to newly diagnosed Pancreatic Ductal Carcinoma (PDAC) cohort.
- ✓ Able to swallow oral medication
- ✓ Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
- ✓ Adequate cardiovascular, hematological, liver, and renal function
- ✓ Willing to comply with all protocol-required visits, assessments, and procedures
You may not qualify if…
- ✕ Previous treatment with a RAS inhibitor
- ✕ Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-0015
- ✕ Received prior palliative radiation within 14 days of Cycle 1, Day 1
- ✕ Have primary central nervous system (CNS) tumors
- ✕ Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption
- ✕ Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs
- ✕ Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial
Where it's recruiting
California
Santa Rosa
Florida
Sarasota · Tampa
Massachusetts
Boston
New York
New York
Texas
Houston · Tyler
Virginia
Fairfax
Source: ClinicalTrials.gov · NCT06983743 · last updated 2026-07-31